BRAF and myeloid sarcoma: The mutation-positive group exhibited significantly higher prevalence of multisystem LCH (88.2% vs. 33.3%, p = 0.008) and advanced-stage disease (p < 0.01), aligning with Nelson et al.’s findings of elevated BRAF mutation rates in MS-LCH versus single-system LCH (60% vs. 30%) (4).